The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Glomerular Localization and Expression of Angiotensin-Converting Enzyme 2 and Angiotensin-Converting Enzyme: Implications for Albuminuria in Diabetes
Abstract
Angiotensin-converting enzyme 2 (ACE2) expression has been shown to be altered in renal tubules from diabetic mice. This study examined the localization of ACE and ACE2 within the glomerulus of kidneys from control (db/m) and diabetic (db/db) mice and the effect of chronic pharmacologic ACE2 inhibition. ACE2 co-localized with glomerular epithelial cell (podocyte) markers, and its localization within the podocyte was confirmed by immunogold labeling. ACE, by contrast, was seen only in glomerular endothelial cells. By immunohistochemistry, in glomeruli from db/db mice, strong ACE staining was found more frequently than in control mice (db/db 64.6 +/- 6.3 versus db/m 17.8 +/- 3.4%; P < 0.005). By contrast, strong ACE2 staining in glomeruli from diabetic mice was less frequently seen than in controls (db/db 4.3 +/- 2.4 versus db/m 30.6 +/- 13.6%; P < 0.05). For investigation of the significance of reduced glomerular ACE2 expression, db/db mice were treated for 16 wk with a specific ACE2 inhibitor (MLN-4760) alone or combined with telmisartan, a specific angiotensin II type 1 receptor blocker. At the end of the study, glomerular staining for fibronectin, an extracellular matrix protein, was increased in both db/db and db/m mice that were treated with MLN-4760. Urinary albumin excretion (UAE) increased significantly in MLN-4760-treated as compared with vehicle-treated db/db mice (743 +/- 200 versus 247 +/- 53.9 microg albumin/mg creatinine, respectively; P < 0.05), and the concomitant administration of telmisartan completely prevented the increase in UAE associated with the ACE2 inhibitor (161 +/- 56; P < 0.05). It is concluded that ACE2 is localized in the podocyte and that in db/db mice glomerular expression of ACE2 is reduced whereas glomerular ACE expression is increased. The finding that chronic ACE2 inhibition increases UAE suggests that ACE2, likely by modulating the levels of glomerular angiotensin II via its degradation, may be a target for therapeutic interventions that aim to reduce albuminuria and glomerular injury.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injury
Kuba, K., Imai, Y., Rao, S., Gao, H., Guo, F., Guan, B., Huan, Y., Yang, P., Zhang, Y., Deng, W., et al. (2005) · Nature Medicine · doi:10.1038/nm1267 · Cited by 3,445
Donoghue, M., Hsieh, F., Baronas, E., Godbout, K., Gosselin, M., Stagliano, N., Donovan, M., Woolf, B., Robison, K., Jeyaseelan, R., et al. (2000) · Circulation Research · doi:10.1161/01.res.87.5.e1 · Cited by 2,485
Angiotensin-converting enzyme 2 protects from severe acute lung failure
Imai, Y., Kuba, K., Rao, S., Huan, Y., Guo, F., Guan, B., Yang, P., Sarao, R., Wada, T., Leong-Poi, H., et al. (2005) · Nature · doi:10.1038/nature03712 · Cited by 2,453
A Human Homolog of Angiotensin-converting Enzyme
Tipnis, S. R., Hooper, N. M., Hyde, R., Karran, E., Christie, G., & Turner, A. J. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m002615200 · Cited by 2,009
Angiotensin-converting enzyme 2 is an essential regulator of heart function
Crackower, M. A., Sarao, R., Oudit, G. Y., Yagil, C., Kozieradzki, I., Scanga, S. E., Oliveira-dos-Santos, A. J., da Costa, J., Zhang, L., Pei, Y., et al. (2002) · Nature · doi:10.1038/nature00786 · Cited by 1,733 · cited 1×
“Although we did not measure AngII levels after ACE2 inhibition, others have shown that in Ace2 knockout, AngII is either endogenously elevated (15,23) or increased above the levels of wild-type mice after infusion of exogenous AngII (24).”
BackgroundTowler, P., Staker, B., Prasad, S. G., Menon, S., Tang, J., Parsons, T., Ryan, D., Fisher, M., Williams, D., Dales, N. A., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m311191200 · Cited by 696
From the Periphery of the Glomerular Capillary Wall Toward the Center of Disease
Wolf, G., Chen, S., & Ziyadeh, F. N. (2005) · Diabetes · doi:10.2337/diabetes.54.6.1626 · Cited by 565
Diabetic kidney disease in the db/db mouse
Sharma, K., McCue, P., & Dunn, S. R. (2003) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00315.2002 · Cited by 521
Endogenous angiotensin concentrations in specific intrarenal fluid compartments of the rat.
Seikaly, M. G., Arant, B. S., & Seney, F. D. (1990) · Journal of Clinical Investigation · doi:10.1172/jci114846 · Cited by 425
Characterization of Renal Angiotensin-Converting Enzyme 2 in Diabetic Nephropathy
Tikellis, C., Johnston, C. I., Forbes, J. M., Burns, W. C., Burrell, L. M., Risvanis, J., & Cooper, M. E. (2003) · Hypertension · doi:10.1161/01.hyp.0000060689.38912.cb · Cited by 350
Cited by
Extrapulmonary manifestations of COVID-19
Gupta, A., Madhavan, M. V., Sehgal, K., Nair, N., Mahajan, S., Sehrawat, T. S., Bikdeli, B., Ahluwalia, N., Ausiello, J. C., Wan, E. Y., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0968-3 · Cited by 3,185
Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19
Ni, W., Yang, X., Yang, D., Bao, J., Li, R., Xiao, Y., Hou, C., Wang, H., Liu, J., Yang, D., et al. (2020) · Critical Care · doi:10.1186/s13054-020-03120-0 · Cited by 1,175
Acute Kidney Injury in COVID-19: Emerging Evidence of a Distinct Pathophysiology
Batlle, D., Soler, M. J., Sparks, M. A., Hiremath, S., South, A. M., Welling, P. A., Swaminathan, S., & on behalf of the COVID-19 and ACE2 in Cardiovascular, L. (2020) · Journal of the American Society of Nephrology · doi:10.1681/asn.2020040419 · Cited by 614
Self-citationImmunity, endothelial injury and complement-induced coagulopathy in COVID-19
Perico, L., Benigni, A., Casiraghi, F., Ng, L. F. P., Renia, L., & Remuzzi, G. (2021) · Nature Reviews Nephrology · doi:10.1038/s41581-020-00357-4 · Cited by 607
Sardu, C., Gambardella, J., Morelli, M. B., Wang, X., Marfella, R., & Santulli, G. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9051417 · Cited by 592
ACE2, angiotensin‐(1‐7) and Mas receptor axis in inflammation and fibrosis
Simões e Silva, A., Silveira, K., Ferreira, A., & Teixeira, M. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12159 · Cited by 542
Kuba, K., Imai, Y., Ohto-Nakanishi, T., & Penninger, J. M. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.06.003 · Cited by 480
COVID-19 and multiorgan failure: A narrative review on potential mechanisms
Mokhtari, T., Hassani, F., Ghaffari, N., Ebrahimi, B., Yarahmadi, A., & Hassanzadeh, G. (2020) · Journal of Molecular Histology · doi:10.1007/s10735-020-09915-3 · Cited by 439
Li, X. C., Zhang, J., & Zhuo, J. L. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.06.005 · Cited by 435
The emerging role of ACE2 in physiology and disease
Hamming, I., Cooper, M., Haagmans, B., Hooper, N., Korstanje, R., Osterhaus, A., Timens, W., Turner, A., Navis, G., & van Goor, H. (2007) · The Journal of Pathology · doi:10.1002/path.2162 · Cited by 434
Recent advances in the angiotensin‐converting enzyme 2–angiotensin(1–7)–Mas axis
Santos, R. A. S., Ferreira, A. J., & Simões e Silva, A. C. (2008) · Experimental Physiology · doi:10.1113/expphysiol.2008.042002 · Cited by 432
Angiotensin-converting enzyme 2 and angiotensin 1–7: novel therapeutic targets
Jiang, F., Yang, J., Zhang, Y., Dong, M., Wang, S., Zhang, Q., Liu, F. F., Zhang, K., & Zhang, C. (2014) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2014.59 · Cited by 426
Covid‐19 and kidney injury: Pathophysiology and molecular mechanisms
Ahmadian, E., Hosseiniyan Khatibi, S. M., Razi Soofiyani, S., Abediazar, S., Shoja, M. M., Ardalan, M., & Zununi Vahed, S. (2021) · Reviews in Medical Virology · doi:10.1002/rmv.2176 · Cited by 366
MECHANISMS IN ENDOCRINOLOGY: Vitamin D and COVID-19
Bilezikian, J. P., Bikle, D., Hewison, M., Lazaretti-Castro, M., Formenti, A. M., Gupta, A., Madhavan, M. V., Nair, N., Babalyan, V., Hutchings, N., et al. (2020) · European Journal of Endocrinology · doi:10.1530/eje-20-0665 · Cited by 343
Angiotensin‐converting enzyme 2 in the brain: properties and future directions
Xia, H., & Lazartigues, E. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05723.x · Cited by 321
Postmortem Kidney Pathology Findings in Patients with COVID-19
Santoriello, D., Khairallah, P., Bomback, A. S., Xu, K., Kudose, S., Batal, I., Barasch, J., Radhakrishnan, J., D’Agati, V., & Markowitz, G. (2020) · Journal of the American Society of Nephrology · doi:10.1681/asn.2020050744 · Cited by 312
Potential effects of curcumin in the treatment of COVID‐19 infection
Zahedipour, F., Hosseini, S. A., Sathyapalan, T., Majeed, M., Jamialahmadi, T., Al‐Rasadi, K., Banach, M., & Sahebkar, A. (2020) · Phytotherapy Research · doi:10.1002/ptr.6738 · Cited by 311
Perico, L., Benigni, A., & Remuzzi, G. (2020) · Nephron · doi:10.1159/000507305 · Cited by 305
Characterization of ACE and ACE2 Expression within Different Organs of the NOD Mouse
Roca-Ho, H., Riera, M., Palau, V., Pascual, J., & Soler, M. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18030563 · Cited by 301
Self-citationWysocki, J., Ye, M., Rodriguez, E., González-Pacheco, F. R., Barrios, C., Evora, K., Schuster, M., Loibner, H., Brosnihan, K. B., Ferrario, C. M., et al. (2010) · Hypertension · doi:10.1161/hypertensionaha.109.138420 · Cited by 300
Self-citationCollapsing glomerulopathy in a COVID-19 patient
Kissling, S., Rotman, S., Gerber, C., Halfon, M., Lamoth, F., Comte, D., Lhopitallier, L., Sadallah, S., & Fakhouri, F. (2020) · Kidney International · doi:10.1016/j.kint.2020.04.006 · Cited by 294
Role of the Intrarenal Renin-Angiotensin-Aldosterone System in Chronic Kidney Disease
Siragy, H. M., & Carey, R. M. (2010) · American Journal of Nephrology · doi:10.1159/000313363 · Cited by 293
Nasal ciliated cells are primary targets for SARS-CoV-2 replication in the early stage of COVID-19
Ahn, J. H., Kim, J., Hong, S. P., Choi, S. Y., Yang, M. J., Ju, Y. S., Kim, Y. T., Kim, H. M., Rahman, M. T., Chung, M. K., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci148517 · Cited by 288
AKI and Collapsing Glomerulopathy Associated with COVID-19 and APOL 1 High-Risk Genotype
Wu, H., Larsen, C. P., Hernandez-Arroyo, C. F., Mohamed, M. M. B., Caza, T., Sharshir, M., Chughtai, A., Xie, L., Gimenez, J. M., Sandow, T. A., et al. (2020) · Journal of the American Society of Nephrology · doi:10.1681/asn.2020050558 · Cited by 282
Loss of Angiotensin-Converting Enzyme-2 (Ace2) Accelerates Diabetic Kidney Injury
Wong, D. W., Oudit, G. Y., Reich, H., Kassiri, Z., Zhou, J., Liu, Q. C., Backx, P. H., Penninger, J. M., Herzenberg, A. M., & Scholey, J. W. (2007) · The American Journal of Pathology · doi:10.2353/ajpath.2007.060977 · Cited by 273
Castrop, H., Höcherl, K., Kurtz, A., Schweda, F., Todorov, V., & Wagner, C. (2010) · Physiological Reviews · doi:10.1152/physrev.00011.2009 · Cited by 269
Reich, H. N., Oudit, G. Y., Penninger, J. M., Scholey, J. W., & Herzenberg, A. M. (2008) · Kidney International · doi:10.1038/ki.2008.497 · Cited by 252
Yan, T., Xiao, R., & Lin, G. (2020) · The FASEB Journal · doi:10.1096/fj.202000782 · Cited by 106
Cross-validation of SARS-CoV-2 responses in kidney organoids and clinical populations
Helms, L., Marchiano, S., Stanaway, I. B., Hsiang, T.-Y., Juliar, B. A., Saini, S., Zhao, Y. T., Khanna, A., Menon, R., Alakwaa, F., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.154882 · Cited by 47
Metadata
- Authors
- Ye, M., Wysocki, J., William, J., Soler, M. J., Cokic, I., & Batlle, D.
- Venue
- Journal of the American Society of Nephrology
- Published
- 2006-11
- Volume
- 17
- Issue
- 11
- Pages
- 3067-3075
- ISSN
- 1046-6673 (ISSN-L)
- OpenAlex
- W2104899725
- Cited by
- 485
- References
- 40
- FWCI
- 11.81
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.